2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer

Keith C. Bible(Mayo Clinic), Electron Kebebew(Stanford University), James D. Brierley(University of Toronto), Juan P. Brito(Mayo Clinic), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Thomas J. Clark(Thermo Fisher Scientific (United States)), Antonio Di Cristofano(Albert Einstein College of Medicine), Robert L. Foote(Mayo Clinic), Thomas J. Giordano(University of Michigan), Jan L. Kasperbauer(Mayo Clinic), Kate Newbold(Royal Marsden NHS Foundation Trust), Yuri E. Nikiforov(University of Pittsburgh), Gregory W. Randolph(Massachusetts Eye and Ear Infirmary), M. Sara Rosenthal(Markey Cancer Center), Anna M. Sawka(University Health Network), Manisha H. Shah(The Ohio State University), Ashok R. Shaha(Memorial Sloan Kettering Cancer Center), Robert C. Smallridge(Jacksonville College), Carol K. Wong-Clark
Thyroid
March 1, 2021
Cited by 692Open Access
Full Text

Abstract

Background: Anaplastic thyroid cancer (ATC) is a rare but highly lethal form of thyroid cancer. Since the guidelines for the management of ATC by the American Thyroid Association were first published in 2012, significant clinical and scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, and researchers on published evidence relating to the diagnosis and management of ATC. Methods: The specific clinical questions and topics addressed in these guidelines were based on prior versions of the guidelines, stakeholder input, and input of the Task Force members (authors of the guideline). Relevant literature was reviewed, including serial PubMed searches supplemented with additional articles. The American College of Physicians Guideline Grading System was used for critical appraisal of evidence and grading strength of recommendations. Results: The guidelines include the diagnosis, initial evaluation, establishment of treatment goals, approaches to locoregional disease (surgery, radiotherapy, targeted/systemic therapy, supportive care during active therapy), approaches to advanced/metastatic disease, palliative care options, surveillance and long-term monitoring, and ethical issues, including end of life. The guidelines include 31 recommendations and 16 good practice statements. Conclusions: We have developed evidence-based recommendations to inform clinical decision-making in the management of ATC. While all care must be individualized, such recommendations provide, in our opinion, optimal care paradigms for patients with ATC.


Related Papers

No related papers found

Powered by citation graph analysis